Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News BioLineRx Ltd BLRX

Healthcare Biotechnology
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BLRX)

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

PR Newswire November 18, 2025

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

PR Newswire November 17, 2025

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

PR Newswire September 29, 2025

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire August 14, 2025

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

PR Newswire August 7, 2025

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire May 27, 2025

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

PR Newswire May 20, 2025

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

PR Newswire March 31, 2025
View More News ››

Opinion & Analysis (NDAQ:BLRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BLRX)

RE:RE:RE:Entry here

There she goes!!!  Patience pays!!!!
mevani - July 2, 2021

RE:RE:Entry here

Patience pays!
mevani - July 1, 2021

RE:Entry here

I am adding here.   
mevani - May 5, 2021

Dang ......

can't win em all
Iseneschal - May 4, 2021

RE:Entry here

Got to be quick.......taking anything it gives me  No position
Iseneschal - May 4, 2021

Entry here

1 st position
Iseneschal - May 4, 2021
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts